Nuvation Bio Inc.
NUVBNYSEHealthcare● Active
$4.92
+$0.10(+2.07%)
Market Cap$1.7B
P/E Ratio—
52W High$9.75
52W Low$1.57
Nuvation Bio Inc. (NUVB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NUVB · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 4, 2026EPS Actual
$0.01
Est. $0.12 · -91.7%
Revenue
$0.08B
Est. $0.07B · +25.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 4, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
NUVB reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.40
Rev. $5.46B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.40
Rev. Est.$5.46B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.15 | — | — | — | $0.03B | — |
| ▼ Q2 FY2026 | May 4, 2026 | $0.12 | $0.01 | -91.7% | $0.08B | $0.07B | +25.7% |
| — Q1 FY2026 | Mar 2, 2026 | -$0.11 | -$0.11 | +0.0% | $0.04B | $0.04B | +10.7% |
| ▲ Q4 FY2025 | Nov 3, 2025 | -$0.17 | -$0.16 | +5.9% | $0.01B | $0.04B | -64.4% |
| — Q3 FY2025 | Aug 7, 2025 | -$0.17 | -$0.17 | +0.0% | $0.00B | $0.00B | +33.4% |
| — Q2 FY2025 | May 7, 2025 | -$0.16 | -$0.16 | +0.0% | $0.00B | $0.00B | +763.5% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -$0.14 | -$0.15 | -7.1% | $0.01B | $0.00B | +585.3% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$0.13 | -$0.15 | -15.4% | $0.00B | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 4, 2026Miss
EPS Actual
$0.01
EPS Est.
$0.12
EPS Surpr.
-91.7%
Revenue
$0.08B
Q1 FY2026
Mar 2, 2026
EPS Actual
-$0.11
EPS Est.
-$0.11
EPS Surpr.
+0.0%
Revenue
$0.04B
Q4 FY2025
Nov 3, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.17
EPS Surpr.
+5.9%
Revenue
$0.01B
Q3 FY2025
Aug 7, 2025
EPS Actual
-$0.17
EPS Est.
-$0.17
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 7, 2025
EPS Actual
-$0.16
EPS Est.
-$0.16
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 6, 2025Miss
EPS Actual
-$0.15
EPS Est.
-$0.14
EPS Surpr.
-7.1%
Revenue
$0.01B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$0.15
EPS Est.
-$0.13
EPS Surpr.
-15.4%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.06 | $-0.05 | $-0.04 | 1 |
| Q3 FY2027 | $-0.08 | $-0.07 | $-0.06 | 1 |
| Q2 FY2027 | $-0.08 | $-0.06 | $-0.05 | 1 |
| Q1 FY2027 | $-0.05 | $-0.04 | $-0.03 | 1 |
| Q4 FY2026 | $-0.12 | $-0.10 | $-0.08 | 1 |
| Q3 FY2026 | $-0.13 | $-0.12 | $-0.11 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2026 | $0.0B | $0.1B | $0.1B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 4, 2026 | -91.7% | $4.49 | $4.41 | -1.78% |
| ▲ Q1 FY2026 | Mar 2, 2026 | +0.0% | $5.91 | $5.84 | -1.18% |
| ▲ Q4 FY2025 | Nov 3, 2025 | +5.9% | $5.22 | $5.17 | -0.96% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +0.0% | $2.35 | $2.34 | -0.43% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $2.09 | $2.04 | -2.39% |
| ▼ Q1 FY2025 | Mar 6, 2025 | -7.1% | $1.87 | $1.89 | +1.07% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -15.4% | $2.32 | $2.54 | +9.48% |
| ▼ Q3 FY2024 | Aug 5, 2024 | -150.0% | $3.36 | $3.18 | -5.36% |
Q2 FY2026-1.78%
Report Date
May 4, 2026
EPS Beat/Miss
-91.7%
Price Before
$4.49
Price After
$4.41
Q1 FY2026-1.18%
Report Date
Mar 2, 2026
EPS Beat/Miss
+0.0%
Price Before
$5.91
Price After
$5.84
Q4 FY2025-0.96%
Report Date
Nov 3, 2025
EPS Beat/Miss
+5.9%
Price Before
$5.22
Price After
$5.17
Q3 FY2025-0.43%
Report Date
Aug 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.35
Price After
$2.34
Q2 FY2025-2.39%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$2.09
Price After
$2.04
Q1 FY2025+1.07%
Report Date
Mar 6, 2025
EPS Beat/Miss
-7.1%
Price Before
$1.87
Price After
$1.89
Q4 FY2024+9.48%
Report Date
Nov 6, 2024
EPS Beat/Miss
-15.4%
Price Before
$2.32
Price After
$2.54
Q3 FY2024-5.36%
Report Date
Aug 5, 2024
EPS Beat/Miss
-150.0%
Price Before
$3.36
Price After
$3.18
Avg Beat Reaction-1.24%
Avg Miss Reaction+0.85%
Beat Rate4 / 8 quarters
Largest Move+9.48% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NUVB ends December
Nuvation Bio Inc. (NUVB) most recently reported earnings on May 4, 2026 for Q2 FY2026, posting EPS of $0.01 — missing the analyst consensus of $0.12 by -91.7%. The next NUVB earnings date is expected around September 1, 2026.
Each quarter, investors track NUVB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NUVB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NUVB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NUVB earnings · 5 questionsNuvation Bio Inc.'s next earnings report is expected around September 1, 2026. NUVB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NUVB historically reports after market close (AMC).
NUVB earnings datewhen is NUVB earningsNUVB next earnings datewhen does NUVB report earningsNUVB earnings calendar
▸ Source: FMP · Nuvation Bio Inc. SEC filings · US GAAP · Nuvation Bio Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026